{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:21Z","timestamp":1791646461916,"version":"4.3.4"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>With increasing decompensation, hyperdynamic circulatory disturbance occurs in liver cirrhosis despite activation of vasoconstrictors. Here, the concept of a therapy with non-selective beta-blockers was established decades ago. They lower elevated portal pressure, protect against variceal hemorrhage, and may also have pleiotropic immunomodulatory effects. Recently, the beneficial effect of carvedilol, which blocks alpha and beta receptors, has been highlighted. Carvedilol leads to \u201cbiased-signaling\u201d <jats:italic>via<\/jats:italic> recruitment of beta-arrestin. This effect and its consequences have not been sufficiently investigated in patients with liver cirrhosis. Also, a number of questions remain open regarding the expression of beta-receptors and its intracellular signaling and the respective consequences in the intra- and extrahepatic tissue compartments. Despite the undisputed role of non-selective beta-blockers in the treatment of liver cirrhosis, we still can improve the knowledge as to when and how beta-blockers should be used in which patients.<\/jats:p>","DOI":"10.3389\/fmed.2022.1100966","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T08:33:40Z","timestamp":1673253220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?"],"prefix":"10.3389","volume":"9","author":[{"given":"Tilman","family":"Sauerbruch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schierwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension.","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut."},{"key":"B2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jhep.2007.02.006","article-title":"Vascular endothelial dysfunction in cirrhosis.","volume":"46","author":"Iwakiri","year":"2007","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis.","volume":"63","author":"Bernardi","year":"2015","journal-title":"J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cgh.2020.08.025","article-title":"Progression of stage 2 and 3 acute kidney injury in patients with decompensated cirrhosis and ascites.","volume":"19","author":"Wong","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.cgh.2015.04.024","article-title":"The art and science of diagnosing and treating lung and heart disease secondary to liver disease.","volume":"13","author":"Goldberg","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cld.141","article-title":"Cirrhotic cardiomyopathy.","volume":"2","author":"Bernardi","year":"2013","journal-title":"Clin Liver Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1053\/j.gastro.2020.07.019","article-title":"Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis.","volume":"159","author":"Bajaj","year":"2020","journal-title":"Gastroenterology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough: the paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology."},{"key":"B9","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy.","volume":"4","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"B10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol\u2013a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study.","volume":"305","author":"Lebrec","year":"1981","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100240","article-title":"Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018).","volume":"12","author":"Gu","year":"2022","journal-title":"Lancet Regional Health Eur."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.dld.2016.09.013","article-title":"Beta blockers and cirrhosis, 2016.","volume":"49","author":"Mandorfer","year":"2017","journal-title":"Dig Liver Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis.","volume":"66","author":"Reiberger","year":"2017","journal-title":"J Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension.","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/liv.13589","article-title":"The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.","volume":"38","author":"M\u00f8ller","year":"2017","journal-title":"Liver Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/0002-9343(58)90322-X","article-title":"Circulatory changes in chronic liver disease.","volume":"24","author":"Murray","year":"1958","journal-title":"Am J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000462974","article-title":"Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis.","volume":"54","author":"Di Pascoli","year":"2017","journal-title":"J Vasc Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"G1043","DOI":"10.1152\/ajpgi.1999.276.4.G1043","article-title":"NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats.","volume":"276","author":"Wiest","year":"1999","journal-title":"Am J Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/gutjnl-2020-320786","article-title":"Targeting the gut-liver-immune axis to treat cirrhosis.","volume":"70","author":"Tranah","year":"2021","journal-title":"Gut."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.718783","article-title":"Bile acids, liver cirrhosis, and extrahepatic vascular dysfunction.","volume":"12","author":"Sauerbruch","year":"2021","journal-title":"Front Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0016-5085(99)70136-8","article-title":"Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis.","volume":"116","author":"Heller","year":"1999","journal-title":"Gastroenterology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/jhep.2001.28794","article-title":"Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism.","volume":"34","author":"Schepke","year":"2001","journal-title":"Hepatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hep.21502","article-title":"Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins.","volume":"45","author":"Hennenberg","year":"2007","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/01.res.56.3.457","article-title":"Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion.","volume":"56","author":"Nicholls","year":"1985","journal-title":"Circ Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJM198212163072504","article-title":"Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.","volume":"307","author":"Bichet","year":"1982","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/s0168-8278(98)80022-6","article-title":"The sympathetic nervous system in liver disease.","volume":"29","author":"Henriksen","year":"1998","journal-title":"J Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.pcad.2016.10.005","article-title":"Beta-adrenergic receptor blockers in hypertension: alive and well.","volume":"59","author":"Frishman","year":"2016","journal-title":"Prog Cardiovasc Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nchembio.1025","article-title":"A new era of GPCR structural and chemical biology.","volume":"8","author":"Granier","year":"2012","journal-title":"Nat Chem Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-pharmtox-010617-053149","article-title":"Serendipitous scientist.","volume":"58","author":"Lefkowitz","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"R575","DOI":"10.1152\/ajpregu.00287.2020","article-title":"\u03b22-Adrenergic receptor agonism as a therapeutic strategy for kidney disease.","volume":"320","author":"Kamiar","year":"2021","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/sj.ijo.0801039","article-title":"The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle.","volume":"23","author":"Chamberlain","year":"1999","journal-title":"Int J Obes Relat Metab Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/s0165-6147(00)01562-5","article-title":"Beta3-adrenoceptors in the cardiovascular system.","volume":"21","author":"Gauthier","year":"2000","journal-title":"Trends Pharmacol Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/RRU.S309144","article-title":"Clinical utility of \u03b23-adrenoreceptor agonists for the treatment of overactive bladder: a review of the evidence and current recommendations.","volume":"14","author":"Krhut","year":"2022","journal-title":"Res Rep Urol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.23222","article-title":"Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.","volume":"50","author":"Trebicka","year":"2009","journal-title":"Hepatology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/bph.15538","article-title":"The concise guide to pharmacology 2021\/22: G protein-coupled receptors.","volume":"178","author":"Alexander","year":"2021","journal-title":"Br J Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-981-10-4810-4_13","article-title":"Cyclic AMP signaling.","author":"Gao","year":"2017","journal-title":"Biology of Vascular Smooth Muscle: Vasoconstriction and Dilatation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/00005344-199106000-00016","article-title":"Nebivolol induces endothelium-dependent relaxations of canine coronary arteries.","volume":"17","author":"Gao","year":"1991","journal-title":"J Cardiovasc Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"\u03b2-Arrestin: a protein that regulates \u03b2-adrenergic receptor function.","volume":"248","author":"Lohse","year":"1990","journal-title":"Science."},{"key":"B41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.tcb.2020.06.002","article-title":"Conformational basis of G protein-coupled receptor signaling versatility.","volume":"30","author":"Wingler","year":"2020","journal-title":"Trends Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cellsig.2018.07.013","article-title":"Differential regulation of \u03b22-adrenoceptor and adenosine A2B receptor signalling by GRK and arrestin proteins in arterial smooth muscle.","volume":"51","author":"Nash","year":"2018","journal-title":"Cell Signal."},{"key":"B43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2362.2009.02181.x","article-title":"Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis.","volume":"39","author":"Hennenberg","year":"2009","journal-title":"Eur J Clin Invest."},{"key":"B44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1478-3231.2009.02010.x","article-title":"Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase?","volume":"29","author":"Hennenberg","year":"2009","journal-title":"Liver Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/bmj.1.5392.1227","article-title":"Hypotensive action of pronethalol.","volume":"1","author":"Prichard","year":"1964","journal-title":"BMJ."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173632","article-title":"\u03b11-adrenoceptor activity of \u03b2-adrenoceptor ligands - an expected drug property with limited clinical relevance.","volume":"889","author":"Michel","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115148","article-title":"Antagonism of \u03b11-adrenoceptors by \u03b23-adrenergic agonists: structure-function relations of different agonists in prostate smooth muscle contraction.","volume":"202","author":"Huang","year":"2022","journal-title":"Biochem Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.cardiores.2004.05.014","article-title":"Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors.","volume":"63","author":"Koshimizu","year":"2004","journal-title":"Cardiovasc Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s002280050628","article-title":"The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.","volume":"55","author":"Gehr","year":"1999","journal-title":"Eur J Clin Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling.","volume":"104","author":"Wisler","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00124","article-title":"Therapeutic potential of targeting \u00df-arrestin.","volume":"10","author":"Bond","year":"2019","journal-title":"Front Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1126\/science.1109237","article-title":"Transduction of receptor signals by beta-arrestins.","volume":"308","author":"Lefkowitz","year":"2005","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"E4107","DOI":"10.1073\/pnas.1606267113","article-title":"\u03b2-arrestin-biased signaling through the \u03b22-adrenergic receptor promotes cardiomyocyte contraction.","volume":"113","author":"Carr","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001564","article-title":"\u03b2-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix.","volume":"3","author":"Lovgren","year":"2011","journal-title":"Sci Transl Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/aps.2015.74","article-title":"The emerging roles of \u03b2-arrestins in fibrotic diseases.","volume":"36","author":"Gu","year":"2015","journal-title":"Acta Pharmacol Sin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"27082","DOI":"10.1073\/pnas.2014337117","article-title":"\u03b2-Arrestin2 is increased in liver fibrosis in humans and rodents.","volume":"117","author":"Schierwagen","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2016.01.022","article-title":"Assessment of response to beta-blockers by expression of \u03b2Arr2 and RhoA\/ROCK2 in antrum mucosa in cirrhotic patients.","volume":"64","author":"Trebicka","year":"2016","journal-title":"J Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/liv.12613","article-title":"Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.","volume":"35","author":"Trebicka","year":"2015","journal-title":"Liver Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1073\/pnas.1922608117","article-title":"\u03b2-Arrestin2 is a critical component of the GPCR\u2013eNOS signalosome.","volume":"117","author":"Liu","year":"2020","journal-title":"PNAS."},{"key":"B61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4254\/wjh.v14.i2.429","article-title":"\u03b2-arrestin-2 predicts the clinical response to \u03b2-blockers in cirrhotic portal hypertension patients: a prospective study.","volume":"14","author":"Lashen","year":"2022","journal-title":"World J Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"14555","DOI":"10.1073\/pnas.0804745105","article-title":"Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation.","volume":"105","author":"Kim","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1111\/bph.15269","article-title":"Metabolic effects of carvedilol through \u03b2-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.","volume":"177","author":"G\u00fcven","year":"2020","journal-title":"Br J Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.1215802","article-title":"Biased signaling pathways in \u03b22-adrenergic receptor characterized by 19F-NMR.","volume":"335","author":"Liu","year":"2012","journal-title":"Science."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.116.024482","article-title":"Long-term biased \u03b2-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy.","volume":"135","author":"Ryba","year":"2017","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol use is associated with reduced cancer risk: a nationwide population-based cohort study.","volume":"184","author":"Lin","year":"2015","journal-title":"Int J Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1940-6207.CAPR-17-0132","article-title":"Topically applied carvedilol attenuates solar ultraviolet radiation induced skin carcinogenesis.","volume":"10","author":"Huang","year":"2017","journal-title":"Cancer Prev Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mc.22820","article-title":"Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention.","volume":"57","author":"Cleveland","year":"2018","journal-title":"Mol Carcinog."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.805318","article-title":"Association between nonselective beta-blocker use and hepatocellular carcinoma in patients with chronic hepatitis b without cirrhosis and decompensation.","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216828","article-title":"The effect of propranolol on the prognosis of hepatocellular carcinoma: a nationwide population-based study.","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One."},{"key":"B71","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.","volume":"73","author":"Trebicka","year":"2020","journal-title":"J Hepatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41575-020-00376-3","article-title":"Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.","volume":"18","author":"Trebicka","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/hep.20037","article-title":"Changing clinical practice with measurements of portal pressure.","volume":"39","author":"Boyer","year":"2004","journal-title":"Hepatology."},{"key":"B74","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/hep.1840020502","article-title":"The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study.","volume":"2","author":"Lebrec","year":"1982","journal-title":"Hepatology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2015.05.011","article-title":"Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy.","volume":"149","author":"Sauerbruch","year":"2015","journal-title":"Gastroenterology."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.06.007","article-title":"Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis.","author":"Jachs","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/jhep.2002.36947","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.","volume":"36","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MEG.0000000000001293","article-title":"Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices.","volume":"31","author":"Zhang","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1572-0241.2007.01759.x","article-title":"Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.","volume":"103","author":"Schepke","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-021-10160-3","article-title":"The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.","volume":"15","author":"Kang","year":"2021","journal-title":"Hepatol Int."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/apt.14576","article-title":"Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.","volume":"47","author":"Schwarzer","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.03.048","article-title":"Short-term hemodynamic effects of \u03b2-blockers influence survival of patients with decompensated cirrhosis.","volume":"73","author":"Alvarado-Tapias","year":"2020","journal-title":"J Hepatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hep.1840020503","article-title":"Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.","volume":"2","author":"Hillon","year":"1982","journal-title":"Hepatology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1080\/00365520500463290","article-title":"Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis.","volume":"41","author":"Schiedermaier","year":"2006","journal-title":"Scand J Gastroenterol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00365529950173726","article-title":"Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state.","volume":"34","author":"Heller","year":"1999","journal-title":"Scand J Gastroenterol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-2362.2003.01131.x","article-title":"Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries.","volume":"33","author":"Neef","year":"2003","journal-title":"Eur J Clin Invest."},{"key":"B89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phrs.2017.01.015","article-title":"The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?","volume":"119","author":"Burza","year":"2017","journal-title":"Pharmacol Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/003655202320378284","article-title":"Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt.","volume":"37","author":"Brensing","year":"2002","journal-title":"Scand J Gastroenterol."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)00574-8","article-title":"Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study.","volume":"77","author":"Alvarado-Tapias","year":"2022","journal-title":"J Hepatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial.","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/liv.14586","article-title":"Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction.","volume":"40","author":"Uschner","year":"2020","journal-title":"Liver Int."},{"key":"B95","doi-asserted-by":"publisher","first-page":"H633","DOI":"10.1152\/ajpheart.00243.2021","article-title":"Immune cell \u03b22-adrenergic receptors contribute to the development of heart failure.","volume":"321","author":"Tanner","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031772","article-title":"Immunomodulatory activity of the most commonly used antihypertensive drugs-angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.","volume":"23","author":"Bryniarski","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00476","article-title":"Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis.","volume":"10","author":"Trebicka","year":"2019","journal-title":"Front Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/intimm\/dxac030","article-title":"Liver cirrhosis and immune dysfunction.","volume":"34","author":"Hasa","year":"2022","journal-title":"Int Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/gutjnl-2020-322621","article-title":"Hepatic inflammasome activation as origin of Interleukin-1\u03b1 and Interleukin-1\u03b2 in liver cirrhosis.","volume":"70","author":"Praktiknjo","year":"2020","journal-title":"Gut."},{"key":"B101","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","article-title":"Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.","volume":"29","author":"Senzolo","year":"2009","journal-title":"Liver Int."},{"key":"B104","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J Hepatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hep.510310109","article-title":"Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites.","volume":"31","author":"P\u00e9rez-Paramo","year":"2000","journal-title":"Hepatology."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/liv.13890","article-title":"Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis.","volume":"38","author":"Gimenez","year":"2018","journal-title":"Liver Int."},{"key":"B107","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12072-020-10083-5","article-title":"Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers.","volume":"14","author":"Almenara","year":"2020","journal-title":"Hepatol Int."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155494","article-title":"Interleukin-6 ablation does not alter morphofunctional heart characteristics but modulates physiological and inflammatory markers after strenuous exercise.","volume":"142","author":"da Rocha","year":"2021","journal-title":"Cytokine."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155497","article-title":"Alpha and beta adrenoceptors activate interleukin-6 transcription through different pathways in cultured astrocytes from rat spinal cord.","volume":"142","author":"Morimoto","year":"2021","journal-title":"Cytokine."},{"key":"B110","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10753-008-9097-8","article-title":"Renal beta(2)-adrenoceptor modulates the lipopolysaccharide transport system in sepsis-induced acute renal failure.","volume":"32","author":"Nakamura","year":"2009","journal-title":"Inflammation."},{"key":"B111","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/gut.47.3.337","article-title":"Functional assessment of beta adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle.","volume":"47","author":"Manara","year":"2000","journal-title":"Gut."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/gut.33.8.1062","article-title":"Modulation of human upper intestinal nutrient transit by a beta adrenoreceptor mediated pathway.","volume":"33","author":"McIntyre","year":"1992","journal-title":"Gut."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8270310","article-title":"Gastrointestinal motility disorders and their clinical implications in cirrhosis.","volume":"2017","author":"Theocharidou","year":"2017","journal-title":"Gastroenterol Res Pract."},{"key":"B114","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1146\/annurev-immunol-042617-053158","article-title":"Molecular and functional neuroscience in immunity.","volume":"36","author":"Pavlov","year":"2018","journal-title":"Annu Rev Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cell.2019.12.002","article-title":"Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss.","volume":"180","author":"Matheis","year":"2020","journal-title":"Cell."},{"key":"B116","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","article-title":"The microbiota in cirrhosis and its role in hepatic decompensation.","volume":"75","author":"Trebicka","year":"2021","journal-title":"J Hepatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJM199105303242202","article-title":"Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group.","volume":"324","author":"Poynard","year":"1991","journal-title":"N Engl J Med."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013121.pub2","article-title":"Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis.","volume":"4","author":"Roccarina","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"S625","DOI":"10.1016\/S0168-8278(22)01568-9","article-title":"Stratified efficacy of first -line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual participant data.","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-0002-2_16","article-title":"Variceal rebleeding: drugs, endoscopy or both.","author":"Bendtsen","year":"2014","journal-title":"Variceal Hemorrhage."},{"key":"B123","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/hep.28318","article-title":"Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + \u03b2-blocker for prevention of variceal rebleeding.","volume":"63","author":"Holster","year":"2016","journal-title":"Hepatology."},{"key":"B124","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)01577-X","article-title":"Covered TIPS reduces the risk of further decompensation: results from an individual patient data meta-analysis of 3924 patients with cirrhosis.","volume":"77","author":"Larrue","year":"2022","journal-title":"J Hepatol."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011510.pub2","article-title":"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","volume":"10","author":"Zacharias","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Faculty. Baveno VII - Renewing consensus in portal hypertension.","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.dld.2020.06.005","article-title":"Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with \u03b2-blockers and ligation.","volume":"52","author":"Ardevol","year":"2020","journal-title":"Dig Liver Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/jhep.1997.v25.pm0008985266","article-title":"Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis.","volume":"25","author":"Bernard","year":"1997","journal-title":"Hepatology."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013122.pub2","article-title":"Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.","volume":"3","author":"Plaz Torres","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B132","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/hep.22358","article-title":"Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding.","volume":"48","author":"Lo","year":"2008","journal-title":"Hepatology."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/hep.29056","article-title":"A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.","volume":"65","author":"Villanueva","year":"2017","journal-title":"Hepatology."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.","volume":"131","author":"D\u2019Amico","year":"2006","journal-title":"Gastroenterology."},{"key":"B135","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/apt.14485","article-title":"Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.","volume":"47","author":"Pfisterer","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/hep.29394","article-title":"Continuation of nonselective beta-blockers for patients with liver cirrhosis and hemodynamic nonresponse?","volume":"66","author":"Sauerbruch","year":"2017","journal-title":"Hepatology."},{"key":"B137","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with \u03b2-blockers.","volume":"107","author":"Hern\u00e1ndez-Gea","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology."},{"key":"B139","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/liv.15166","article-title":"Non-selective beta-blockers in patients with ascites: the complex interplay among the liver, kidney and heart.","volume":"42","author":"T\u00e9llez","year":"2022","journal-title":"Liver Int."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non-selective \u03b2-blockers are associated with improved survival in patients with ascites listed for liver transplantation.","volume":"64","author":"Leithead","year":"2015","journal-title":"Gut."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/liv.13409","article-title":"Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.","volume":"37","author":"Onali","year":"2017","journal-title":"Liver Int."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/liv.13119","article-title":"Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.","volume":"36","author":"Bang","year":"2016","journal-title":"Liver Int."},{"key":"B143","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/1060028019893092","article-title":"Use of nonselective \u03b2-blockers in patients with end-stage liver disease and select complications.","volume":"54","author":"Bultas","year":"2020","journal-title":"Ann Pharmacother."},{"key":"B144","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis.","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology."},{"key":"B145","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/gut.2009.180570","article-title":"Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.","volume":"59","author":"Krag","year":"2010","journal-title":"Gut."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/gutjnl-2016-312129","article-title":"Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters.","volume":"65","author":"Njei","year":"2016","journal-title":"Gut."},{"key":"B147","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.20284","article-title":"Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.","volume":"40","author":"Schepke","year":"2004","journal-title":"Hepatology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2036.2005.02346.x","article-title":"Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding.","volume":"21","author":"Khuroo","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1053\/jhep.2001.29305","article-title":"Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?","volume":"34","author":"Abraczinskas","year":"2001","journal-title":"Hepatology."},{"key":"B150","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hep.1840070306","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding.","volume":"7","author":"Poynard","year":"1987","journal-title":"Hepatology."},{"key":"B151","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.0889-7204.2004.02896.x","article-title":"Adherence to long-term therapies management: a call for cardiovascular nursing managers and policymakers.","volume":"19","author":"Sabat\u00e9","year":"2004","journal-title":"Prog Cardiovasc Nurs."},{"key":"B152","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(18)33079-4","article-title":"Confronting the most challenging risk factor: non-adherence.","volume":"393","author":"Kones","year":"2019","journal-title":"Lancet."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jama.2014.10059","article-title":"Electronic medication packaging devices and medication adherence: a systematic review.","volume":"312","author":"Checchi","year":"2014","journal-title":"JAMA."},{"key":"B154","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.2147\/IJGM.S326192","article-title":"Adherence to non-selective beta blockers for prevention of variceal bleeding in cirrhotic patients.","volume":"14","author":"An","year":"2021","journal-title":"Int J Gen Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jocn.13083","article-title":"Factors associated with medication adherence in patients living with cirrhosis.","volume":"25","author":"Polis","year":"2016","journal-title":"J Clin Nurs."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/hep.31548","article-title":"Appropriate and potentially inappropriate medication use in decompensated cirrhosis.","volume":"73","author":"Thomson","year":"2021","journal-title":"Hepatology."},{"key":"B157","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hep4.1334","article-title":"Medication-related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention.","volume":"3","author":"Hayward","year":"2019","journal-title":"Hepatol Commun."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/imj.14986","article-title":"Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis.","volume":"50","author":"Hayward","year":"2020","journal-title":"Intern Med J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/gut.30.2.228","article-title":"Pressure of intraoesophageal varices assessed by fine needle puncture: its relation to endoscopic signs and severity of liver disease in patients with cirrhosis.","volume":"30","author":"Kleber","year":"1989","journal-title":"Gut."},{"key":"B160","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/0016-5085(91)70021-O","article-title":"Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study.","volume":"100","author":"Kleber","year":"1991","journal-title":"Gastroenterology."},{"key":"B161","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJM198810133191505","article-title":"Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study.","volume":"319","year":"1988","journal-title":"N Engl J Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jhep.2015.11.039","article-title":"Esophageal varices: stage-dependent treatment algorithm.","volume":"64","author":"Bosch","year":"2016","journal-title":"J Hepatol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices.","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg."},{"key":"B164","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology."},{"key":"B165","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: liver transplantation.","volume":"64","year":"2016","journal-title":"J Hepatol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cgh.2008.06.018","article-title":"Elevated soluble tumor necrosis factor receptor 75 concentrations identify patients with liver cirrhosis at risk of death.","volume":"6","author":"Gr\u00fcnhage","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jhep.2014.11.012","article-title":"The CLIF consortium acute decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.","volume":"62","author":"Jalan","year":"2015","journal-title":"J Hepatol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jhep.2020.11.019","article-title":"PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.","volume":"74","author":"Trebicka","year":"2021","journal-title":"J Hepatol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jhep.2013.05.009","article-title":"EASL recognition awardee 2013: Dr. Didier Lebrec.","volume":"59","author":"Sauerbruch","year":"2013","journal-title":"J Hepatol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease.","volume":"6","author":"Bosch","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3791\/58819","article-title":"Measurement of the hepatic venous pressure gradient and transjugular liver biopsy.","volume":"160","author":"Reiberger","year":"2020","journal-title":"J Vis Exp."},{"key":"B172","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study.","volume":"111","author":"Vorobioff","year":"1996","journal-title":"Gastroenterology."},{"key":"B173","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/hep.20386","article-title":"Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.","volume":"40","author":"Monescillo","year":"2004","journal-title":"Hepatology."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding.","volume":"362","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"N Engl J Med."},{"key":"B175","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(95)91740-3","article-title":"Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis.","volume":"346","author":"Feu","year":"1995","journal-title":"Lancet."},{"key":"B176","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jhep.2009.04.015","article-title":"Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.","volume":"51","author":"La Mura","year":"2009","journal-title":"J Hepatol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","article-title":"Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis.","volume":"18","author":"Turco","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.gastro.2009.03.048","article-title":"Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.","volume":"137","author":"Villanueva","year":"2009","journal-title":"Gastroenterology."},{"key":"B179","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep4.1855","article-title":"The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis.","volume":"6","author":"Reiberger","year":"2022","journal-title":"Hepatol Commun."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1046\/j.1365-2036.1999.00622.x","article-title":"Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis.","volume":"13","author":"Schepke","year":"1999","journal-title":"Aliment Pharmacol Ther."},{"key":"B181","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.3748\/wjg.v21.i23.7191","article-title":"\u03b2-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.","volume":"21","author":"Kong","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/jgh.13198","article-title":"Influence of CYP2D6 and \u03b22-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis.","volume":"31","author":"Zhang","year":"2016","journal-title":"J Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1100966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:51:21Z","timestamp":1674049881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1100966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":182,"alternative-id":["10.3389\/fmed.2022.1100966"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1100966","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1100966"}}